胶质母细胞瘤患者是发生静脉血栓栓塞 (VTE) 风险最高的癌症患者之一。由于胶质母细胞瘤患者对颅内出血的易感性增加，通常不进行长期血栓预防。本综述概述了胶质母细胞瘤患者的当前临床标准，以及导致 VTE 高发生率的分子和遗传背景。除了可能与胶质母细胞瘤高凝状态相关的遗传畸变外，还描述了参与胶质母细胞瘤相关 VTE 的两种主要促凝血蛋白：足足蛋白和组织因子。此外，还讨论了可能的新型生物标志物和未来的治疗策略，以及测序方法对 VTE 个性化风险预测的潜力。胶质母细胞瘤特异性 VTE 风险分层模型可能有助于识别那些因延长抗凝治疗而增加的出血风险被 VTE 风险降低所抵消的患者。作者。这是 Thieme 根据知识共享署名许可条款发表的开放获取文章，只要正确引用原始作品，就允许不受限制地使用、分发和复制。 （https://creativecommons.org/licenses/by/4.0/）。

Patients with glioblastoma are among the cancer patients with the highest risk of developing venous thromboembolism (VTE). Long-term thromboprophylaxis is not generally prescribed because of the increased susceptibility of glioblastoma patients to intracranial hemorrhage. This review provides an overview of the current clinical standard for glioblastoma patients, as well as the molecular and genetic background which underlies the high incidence of VTE. The two main procoagulant proteins involved in glioblastoma-related VTE, podoplanin and tissue factor, are described, in addition to the genetic aberrations that can be linked to a hypercoagulable state in glioblastoma. Furthermore, possible novel biomarkers and future treatment strategies are discussed, along with the potential of sequencing approaches toward personalized risk prediction for VTE. A glioblastoma-specific VTE risk stratification model may help identifying those patients in which the increased risk of bleeding due to extended anticoagulation is outweighed by the decreased risk of VTE.The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).